Immunotherapy Outcomes in Individuals With Non–Small Cell Lung Cancer and Poor Performance Status

Abstract Background Patients with non–small cell lung cancer (NSCLC) treated in real-world practice typically have worse performance status (PS) compared with clinical trial patients, and the effectiveness of immunotherapy in this population in unknown. In this study, we assessed the effectiveness of standard of care immunotherapy for the first-line treatment of stage IV patients with NSCLC with Eastern Cooperative Oncology Group (ECOG) PS greater than or equal to 2. Methods We selected ECOG PS greater than or equal to 2 patients from real-world oncology data from a deidentified database and included them if they were diagnosed with stage IV NSCLC and had documented Programmed death-ligand 1 [PD-(L)1] expression greater than 0. Patients with tumor PD-(L)1 expression of at least 50% treated with pembrolizumab monotherapy were compared with those who did not have any documented treatment. Patients with tumor PD-(L)1 expression less than 50% treated with pembrolizumab and chemotherapy were compared with those treated with pembrolizumab monotherapy and those without documented treatment. Results In our propensity score–adjusted analysis, patients with ECOG PS of at least 2 and tumor PD-(L)1 expression of at least 50% treated with pembrolizumab monotherapy had statistically significantly better real-world overall survival compared with those without documented treatment (adjusted hazard ratio [HR] = 0.39, 95% confidence internal [CI] = 0.32 to 0.47). For patients with tumor PD-(L)1 expression less than 50%, there was also a statistically significant real-world overall survival benefit for those who received treatment either with combination pembrolizumab plus chemotherapy (adjusted HR = 0.39, 95% CI = 0.32 to 0.46) or pembrolizumab monotherapy (adjusted HR = 0.55, 95% CI = 0.41 to 0.70) compared with patients receiving no documented treatment. Conclusions Among a highly representative sample of patients with advanced NSCLC and poor PS, our findings suggest that immunotherapy may provide an important survival benefit in individuals with high PD-(L)1–expressing tumors and in conjunction with chemotherapy in tumors with low PD-(L)1 expression.

[1]  Page Widick,et al.  Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy , 2021, JAMA network open.

[2]  J. Heymach,et al.  Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status , 2020, Journal for ImmunoTherapy of Cancer.

[3]  L. Landi,et al.  First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. , 2020, European journal of cancer.

[4]  S. Baxi,et al.  Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR , 2020 .

[5]  Michael J. Lopez,et al.  Estimation of causal effects of multiple treatments in observational studies with a binary outcome , 2020, Statistical methods in medical research.

[6]  Sandra D Griffith,et al.  Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set , 2019, JCO clinical cancer informatics.

[7]  Joseph W Hogan,et al.  Causal comparative effectiveness analysis of dynamic continuous‐time treatment initiation rules with sparsely measured outcomes and death , 2019, Biometrics.

[8]  A. Abernethy,et al.  Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint , 2018, Health services research.

[9]  Liangyuan Hu,et al.  Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[11]  Peter C. Austin,et al.  Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis , 2016, Statistics in medicine.

[12]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[13]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[14]  A. Ganti,et al.  Management of patients with lung cancer and poor performance status. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  J. Cashy,et al.  Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  M. J. van der Laan,et al.  Statistical Applications in Genetics and Molecular Biology Super Learner , 2010 .

[17]  N. Freemantle,et al.  Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. , 2006, The Lancet. Oncology.

[18]  Joy H. Lewis,et al.  Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Krook,et al.  Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 , 2001, Cancer.

[20]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[21]  M. Jiroutek.  Prognostic factors in advanced non-small cell lung cancer: Analysis of Eastern Cooperative Oncology group trials from 1981-1992 , 1998 .